In terms of anaemia management, although usage of erythropoietin-stimulating agents (ESA) was relatively lower in HHD patients compared to in-centre HD (Figure 3), we did not report any statistically significant differences between both modalities in haemoglobin levels, ESA usage, or weekly units of ESA. This evidence concerns the gene EPO and anemia.